Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system

Simple item page
dc.catalogadoryvc
dc.contributor.authorOcaranza Jeraldino, María Paz
dc.contributor.authorMichea, Luis
dc.contributor.authorChiong, Mario
dc.contributor.authorLagos Arévalo, Carlos Fernando
dc.contributor.authorLavandero, Sergio
dc.contributor.authorJalil Milad, Jorge Emilio
dc.date.accessioned2024-06-10T01:23:34Z
dc.date.available2024-06-10T01:23:34Z
dc.date.issued2014
dc.description.abstractChronic RAS (renin-angiotensin system) activation by both AngII (angiotensin II) and aldosterone leads to hypertension and perpetuates a cascade of pro-hypertrophic, pro-inflammatory, pro-thrombotic and atherogenic effects associated with cardiovascular damage. In 2000, a new pathway consisting of ACE2 (angiotensin-converting enzyme2), Ang-(1-9) [angiotensin-(1-9)], Ang-(1-7) [angiotensin-(1-7)] and the Mas receptor was discovered. Activation of this novel pathway stimulates vasodilation, anti-hypertrophy and anti-hyperplasia. For some time, studies have focused mainly on ACE2, Ang-(1-7) and the Mas receptor, and their biological properties that counterbalance the ACE/AngII/AT(1)R (angiotensin type 1 receptor) axis. No previous information about Ang-(1-9) suggested that this peptide had biological properties. However, recent data suggest that Ang-(1-9) protects the heart and blood vessels (and possibly the kidney) from adverse cardiovascular remodelling in patients with hypertension and/or heart failure. These beneficial effects are not modified by the Mas receptor antagonist A779 [an Ang-(1-7) receptor blocker], but they are abolished by-the AT(2)R (angiotensin type 2 receptor) antagonist PD123319. Current information suggests that the beneficial effects of Ang-(1-9) are mediated via the AT2R. In the present review, we summarize the biological effects of the novel vasoactive peptide Ang-(1-9), providing new evidence of its cardiovascular-protective activity. We also discuss the potential mechanism by which this peptide prevents and ameliorates the cardiovascular damage induced by RAS activation.
dc.description.funderFONDEF
dc.fechaingreso.objetodigital2024-06-09
dc.fuente.origenHistorial Académico
dc.identifier.citationOcaranza M, Lagos C, Jalil J, Michea L, Chiong M, Lavandero S. Recent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system. Clinical Science. 2014;127(9-10):549-557.
dc.identifier.doi10.1042/CS20130449
dc.identifier.issn0143-5221
dc.identifier.urihttps://doi.org/10.1042/CS20130449
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/86654
dc.identifier.wosidWOS:000342405600001
dc.information.autorucEscuela de Medicina; Ocaranza Jeraldino, María Paz; 0000-0002-4915-6378; 1001254
dc.information.autorucEscuela de Medicina; Lagos Arévalo, Carlos Fernando; 0000-0002-5432-9747; 7337
dc.information.autorucEscuela de Medicina; Jalil Milad, Jorge Emilio; 0000-0001-6877-2072; 99946
dc.issue.numero9-10
dc.nota.accesocontenido parcial
dc.pagina.final557
dc.pagina.inicio549
dc.revistaClinical Science
dc.rightsacceso restringido
dc.subjectAngiotensin-(1–9)
dc.subjectAngiotensin II
dc.subjectAngiotensin type 2 receptor (AT2R)
dc.subjectCardiovascular damage
dc.subjectRenin–angiotensin system
dc.subject.ddc610
dc.subject.deweyMedicina y saludes_ES
dc.titleRecent insights and therapeutic perspectives of angiotensin-(1-9) in the cardiovascular system
dc.typeartículo
dc.volumen127
sipa.codpersvinculados1001254
sipa.codpersvinculados7337
sipa.codpersvinculados99946
sipa.trazabilidadHistorial Académico;09-07-2021
sipa.trazabilidadORCID;2024-06-09
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
RESUMEN_Recent insights and therapeutic perspectives of angiotensin.pdf
Size:
104.81 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas